The purpose of this pilot study is to obtain a preliminary assessment of the antiviral activity and tolerability of Kaletra single agent therapy as initial treatment for HIV infection, relative to a Kaletra three drug standard of care reference arm

OR more than 3 mutations from the other points of the LPV mutation score:10,20,24,46,53,54,63,71

in the reverse transcriptase : 215 or 184.

If abnormal laboratory results such as :

Hb<8 g/dl

Absolute neutrophil count<750 cells/µl

Platelet count<50 000/ml

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00234923